Document Detail


Idazoxan does not prevent but worsens focal hypoxic-ischemic brain damage in neonatal Wistar rats.
MedLine Citation:
PMID:  10561697     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We examined the neuroprotective efficacy of a post-treatment with idazoxan (Idaz): an alpha2-adrenoceptor antagonist with activity at the I1- and I2-subtypes of the imidazoline receptor (I-receptor), in an experimental model of perinatal hypoxic-ischemic (HI) brain damage. Seventy-two, 7-day-old Wistar rats were subjected to permanent unilateral ligation of the common carotid artery and transient (2 hr) hypoxia (8% O(2)). The surviving animals were sub-divided into 3 groups: one "control" group received intraperitoneal (i.p.) injection of saline (Sigma; n = 21) and two "treated" groups received, 10 min post-HI, i.p. treatments with Idaz (I3: 3 mg/kg; n = 19) or (I8: 8 mg/kg; n = 20). Idaz effects were assessed by TTC-staining 72 hr post-HI for Sigma (n = 13), I3 (n = 11), and I8 (n = 12) groups and by MRI-examination 5 weeks post-HI for Sigma (n = 8), I3 (n = 8), and I8 (n = 6) groups. Total ratio of brain infarct areas were significantly (P < 0.01) different between Sigma and Idaz-treated rats: 20.9 +/- 4.0%, 35.6 +/- 5.9 % and 36.8 +/- 5.8% for Sigma, I3 and I8, respectively, when determined with TTC-staining and; 23.3 +/- 3.7%, 39.8 +/- 4.2%, and 43.2 +/- 10.1%, for Sigma, I3, and I8, respectively, when assessed by MRI. Our results suggest that Idaz, given as a post-HI treatment, does not exert neuroprotective effects but enhances the brain injury induced by focal neonatal cerebral HI. The deleterious mechanism may result from an overactivity of sympathetic tone and/or the immaturity of central I-receptors in newborn rats.
Authors:
D Antier; F Franconi; F Sannajust
Related Documents :
7499557 - Time-course of neuropeptide changes in peri-ischemic zone and amygdala following focal ...
18262367 - D-jnki, a peptide inhibitor of c-jun n-terminal kinase, promotes functional recovery af...
19268597 - Neuronal protective effects of focal ischemic pre- and/or postconditioning on the model...
7530927 - Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage.
11303167 - Ultrastructural and functional characteristics of blast injury-induced neurotrauma.
1937147 - Increased sod activities and decreased lipid peroxide levels induced by low dose x irra...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of neuroscience research     Volume:  58     ISSN:  0360-4012     ISO Abbreviation:  J. Neurosci. Res.     Publication Date:  1999 Dec 
Date Detail:
Created Date:  2000-01-05     Completed Date:  2000-01-05     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  7600111     Medline TA:  J Neurosci Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  690-6     Citation Subset:  IM    
Copyright Information:
Copyright 1999 Wiley-Liss, Inc.
Affiliation:
EA-2641, Department of Neuropharmacology, Faculty of Pharmacy, Tours, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Animals, Newborn
Brain / pathology
Brain Ischemia / drug therapy*,  pathology
Idazoxan / adverse effects*,  therapeutic use*
Magnetic Resonance Imaging
Rats
Rats, Wistar
Chemical
Reg. No./Substance:
79944-58-4/Idazoxan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Autocrine alpha-melanocyte-stimulating hormone inhibits NF-kappaB activation in human glioma.
Next Document:  CDP-choline: neuroprotection in transient forebrain ischemia of gerbils.